Seoul: Unionized workers at Samsung Biologics, the biotech arm of Samsung Group, continued to stage a strike Saturday for a second day, according to union officials, with the union and the company showing little signs of bridging gaps over wages and other issues.

According to Yonhap News Agency, the union of Samsung Biologics began the strike on Friday, marking the first walkout since the company's establishment in 2011. The union is seeking a 14 percent increase in both base and performance-related pay, a one-off cash incentive of 30 million won per worker, and bonuses equivalent to 20 percent of annual operating profit. The company, on the other hand, has proposed a combined 6.2 percent increase in base and performance pay.

The ongoing strike highlights the growing tensions between labor and management within the company, as both parties remain firm on their positions. The union argues that their demands are reasonable and reflect the company's strong financial performance. In contrast, the company maintains that their offer is fair and sustainable in the current economic climate. As negotiations continue, the strike has drawn significant attention, given Samsung Biologics' prominent role in the biotech industry.